N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=91 Dementia With Lewy Bodies - Infinitome
Dementia With Lewy Bodies
Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score
N/A N=49 Cognitive Dysfunction in Parkinson's Disease
Parkinson's Disease
Primary: Change in Magnetoencephalography (MEG) Connectivity Measures
N/A N=30 Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders
Conversion Disorder
Primary: Gray Matter Volume Biomarkers of 6 Month Prognosis as Measured by Voxel Based Morphometry - Within Group Comparison — 4.18; 3.27; 3.85; 3.76 peak voxel z-score
N/A N=19 Bipolar Disorder in Late Life
Bipolar Disorder
Primary: Boyko DWM Hyperintensity Value >2 in Subjects Who Received Acute Treatment for Mania — 10; 9 participants — p=>0.05
N/A N=46 Neurologic Injuries in Adults With Urea Cycle Disorders
Brain Diseases, Metabolic, Inborn · Urea Cycle Disorder · Ornithine Transcarbamylase Deficiency
Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003
N/A N=45 Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia
Alzheimer's Disease · Frontotemporal Dementia, Behavioral Variant
Primary: Change in Clinical Disease Severity (CDR) — -0.1; 0.0; 0.0; 0.0 score on a scale
N/A N=93 Neuroplasticity in TBI and Schizophrenia
Schizophrenia · Traumatic Brain Injury
Primary: Mismatch Negativity (MMN) Amplitudes in Microvolts — -0.59; -1.19; -0.41; -0.65 microvolts
N/A N=35 Neural Bases of Cognitive Rehabilitation for Brain Injury
Brain Injury
Primary: Change From Baseline on a Composite Measure (Z-score) of Attention, Working Memory, and Executive Functions — 0.26; .01 Change to Z (composite) score
N/A N=24 Traumatic Brain Injury and Risk for Chronic Traumatic Encephalopathy
CTE · TBI (Traumatic Brain Injury)
Primary: Distribution Volume Ratio (DVR) — 1.30; 1.39; 1.26; 1.34 Distribution Volume Ratio (DVR) — p=<0.02
Early Phase 1 N=138 Drugs Brain and Behavior (DDP)
Stimulant Use
Primary: Change in SUbjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 19.2; 57.8…
Phase 4 N=57 Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa
Depression
Primary: Change in Functional Corticostriatal Connectivity — 0.10; 0.04; 0.07; 0.00 Z-score
N/A N=42 Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study
Mild Cognitive Impairment · Alzheimer Disease · Vascular Dementia
Primary: Percentage of Recruited Subjects Able to Comply With the Protocol — 12; 13; 3; 14 Participants
N/A N=15 Neural Signatures of Parkinson's Disease
Parkinson's Disease
Primary: Change in Resting State Beta Band Power Over Time — -0.28 regression beta coefficient — p=0.038
Phase 2 N=20 Effect of Insulin Sensitizer Metformin on AD Biomarkers
Alzheimer's Disease · Vascular Dementia · Dementia
Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled
N/A N=57 Aerobic Exercise in Parkinson's Disease
Parkinson's Disease
Primary: Change in MDS-UPDRS Part III Motor (OFF) Score — 0.44; -2.96 score on scale — p=>0.05
N/A N=30 Triglyceride Effects on Blood Flow in the Human Brain
Alzheimer Disease
Primary: Cerebral Blood Flow Global — -2.2 ml/100g/min — p=.002
Phase 2 N=5 Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
Diffuse Lewy Body Disease · Dementia With Lewy Bodies · Parkinson's Disease Dementia
Primary: Absolute 11C-PBR28 Binding (Total Distribution Volume Corrected for Free Fraction in Plasma) — 0.15 kBq·cm-3 / kBq·mL-1
N/A N=62 Training in Ataxia - Individuals With Degenerative Cerebellar Diseases
Cerebellar Ataxia
Primary: Change in Assessment and Rating of Ataxia (SARA) Score — -2.4; -0.9; -1.5; -0.2 score on a scale
N/A N=10 Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease
Alzheimer Disease
Primary: Change in Connectivity Measure of the TGd Parcellations. — 0.5 abnormal connections
Phase 4 N=95 Brain Aging and Treatment Response in Geriatric Depression
Mild Cognitive Impairment (MCI) · Depression
Primary: Change in Hamilton Depression Rating Scale — 17.8; 17.7; 6.0; 6.7 units on a scale
N/A N=212 Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease
Anemia, Sickle Cell
Primary: Wechsler Adult Intelligence Scale (WAIS)-III Performance IQ — 90.6; 95.9 Points on a scale — p=0.008
Phase 2 N=90 Image Parkinson's Disease Progression Study
Parkinson's Disease
Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)
Phase 2 N=30 The Efficient Brain Study
Metabolism - Cerebral Energy
Primary: Magnetic Resonance Spectroscopy (MRS) Will Measure a Change in Cerebral Energy Function in Brain Tissue — .011; .007; .009; .006 Difference in metabolite amplitude
N/A N=9 BRAIN, Symptoms, and Physical Activity in COPD
COPD · Chronic Musculoskeletal Pain
Primary: Cortical Thickness — 2.2 mm
Phase 1 N=52 Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI)
Mild Cognitive Impairment · Alzheimer's Disease · Traumatic Brain Injury
Primary: Memory Test Accuracy on Trained Stimuli — 53.9; 37.6; 48.9; 37.3 Percent correct
Phase 4 N=260 A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms
Parkinsonian Syndromes
Primary: Changes That the Doctor Made in the Clinical Management of Subjects Based Upon the Impact of the Imaging Product. — 33; 28; 19; 11 Number of changes in clinical management
N/A N=51 Physiological Effects of Nutritional Support in Patients With Parkinson's Disease
Parkinson Disease · Idiopathic Parkinson Disease
Primary: Distribution Volume Ratio — 2.65; 2.70; 2.96; 2.74 Distribution volume ratios — p=0.05
N/A N=11 Cerebrovascular Dysregulation in Chronic Kidney Disease
Chronic Kidney Diseases
Primary: Mean Arterial Pressure-Middle Cerebral Artery Blood Velocity Very Low Frequency Phase (Radians) — 1.38; 1.12; 1.40; 1.60 Radians — p=0.05
Phase 2 N=11 Endothelial Facilitation in Alzheimer's Disease
Alzheimer's Disease
Primary: Mean Change in Cerebral Blood Flow as Measured by Magnetic Resonance Imaging (MRI) — 0.621528; 0.6447692; 0.654822667; 0.579838667 ml/110g/min